Park Ha Biological Technology is trading 7.9% down at $0.34 following headlines regarding a class-action lawsuit alleging a fraudulent stock promotion scheme.

  • Pre-market traders appear focused on heightened legal and reputational risks, pressuring the shares.
  • The downward move comes despite a broadly positive backdrop in the U.S. market.